164 related articles for article (PubMed ID: 38177135)
21. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
[TBL] [Abstract][Full Text] [Related]
23. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.
Gao Y; Ge G; Ji H
Protein Cell; 2011 Feb; 2(2):99-107. PubMed ID: 21380642
[TBL] [Abstract][Full Text] [Related]
24. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
Qian M; Yan F; Wang W; Du J; Yuan T; Wu R; Zhao C; Wang J; Lu J; Zhang B; Lin N; Dong X; Dai X; Dong X; Yang B; Zhu H; He Q
Acta Pharm Sin B; 2021 Dec; 11(12):4008-4019. PubMed ID: 35024322
[TBL] [Abstract][Full Text] [Related]
25. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
[TBL] [Abstract][Full Text] [Related]
26. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
Koivunen JP; Kim J; Lee J; Rogers AM; Park JO; Zhao X; Naoki K; Okamoto I; Nakagawa K; Yeap BY; Meyerson M; Wong KK; Richards WG; Sugarbaker DJ; Johnson BE; Jänne PA
Br J Cancer; 2008 Jul; 99(2):245-52. PubMed ID: 18594528
[TBL] [Abstract][Full Text] [Related]
27. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
[TBL] [Abstract][Full Text] [Related]
28. LKB1 promotes metabolic flexibility in response to energy stress.
Parker SJ; Svensson RU; Divakaruni AS; Lefebvre AE; Murphy AN; Shaw RJ; Metallo CM
Metab Eng; 2017 Sep; 43(Pt B):208-217. PubMed ID: 28034771
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
[TBL] [Abstract][Full Text] [Related]
30. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY
Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628
[TBL] [Abstract][Full Text] [Related]
31. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
32. The deubiquitinase JOSD2 is a positive regulator of glucose metabolism.
Krassikova L; Zhang B; Nagarajan D; Queiroz AL; Kacal M; Samakidis E; Vakifahmetoglu-Norberg H; Norberg E
Cell Death Differ; 2021 Mar; 28(3):1091-1109. PubMed ID: 33082514
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
34. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.
Hawley SA; Boudeau J; Reid JL; Mustard KJ; Udd L; Mäkelä TP; Alessi DR; Hardie DG
J Biol; 2003; 2(4):28. PubMed ID: 14511394
[TBL] [Abstract][Full Text] [Related]
35. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
36. Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
Lung Cancer; 2015 May; 88(2):131-8. PubMed ID: 25769882
[TBL] [Abstract][Full Text] [Related]
37. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
38. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD; Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK
Cancer Discov; 2013 Aug; 3(8):870-9. PubMed ID: 23715154
[TBL] [Abstract][Full Text] [Related]
39. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
[TBL] [Abstract][Full Text] [Related]
40. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
